Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)				1 Months Ended	12 Months Ended		20 Months Ended
		Oct. 16, 2021	Jul. 01, 2021	May 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	Aug. 31, 2021	Aug. 12, 2021	Dec. 31, 2019	Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price					$ 50,900,000
Proceeds from related party					5,000,000.0
Deferred revenue					20,370,000	$ 34,937,000				$ 40,847,000
Deferred revenue - current					827,000	33,275,000
Deferred revenue - non-current					19,543,000	1,662,000
Revenue' collaborations and services					75,442,000	65,144,000
Deferred revenue					20,370,000	34,937,000				$ 40,847,000
Deferred revenue — current					827,000	33,275,000
Deferred revenue — long term					19,543,000	1,662,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services					36,274,000	32,820,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services					39,168,000	32,324,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received											$ 45,000,000.0
Milestone Payment Received							$ 12,500,000
Total transaction price					50,900,000
Total anticipated cash flows	[1]	$ 463,500,000
Deferred revenue					18,600,000
Deferred revenue - current					600,000
Deferred revenue - non-current					18,000,000.0
Deferred revenue					18,600,000
Deferred revenue — current					600,000
Deferred revenue — long term					18,000,000.0
Collaboration and License Agreement | United Therapeutics Corporation | Clinical Supplies
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price					105,800,000
Collaboration and License Agreement | United Therapeutics Corporation | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional option exercise and development milestone payments to be receive					40,000,000.0
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Allocated transaction price		144,500,000
Revenue recognized during period					$ 0
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		64,300,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows		$ 399,200,000
Collaboration and License Agreement | Tyvaso DPI
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flows								$ 221,500,000	$ 221,500,000
Commercial Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amendment description					As amended by an amendment dated October 16, 2021, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) United Therapeutics provides notice to the Company at least 24 months in advance of such renewal that United Therapeutics does not wish to renew the CSA or (ii) the Company provides notice to United Therapeutics at least 48 months in advance of such renewal that the Company does not wish to renew the CSA.
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services					$ 267,000
Co-Promotion Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Impairment on contract assets related to variable consideration					100,000
Co-Promotion Agreement | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reserve for allowance for doubtful accounts					800,000
Co-Promotion Agreement | Vertice Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price					6,300,000
Amendment to Co Promotion Agreement | Vertice Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of modification of previously fixed consideration			50.00%
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services					0	200,000
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue					1,700,000
Deferred revenue - current					100,000
Deferred revenue - non-current					1,600,000
Marketing and distribution agreement date				2018-05
Deferred revenue					1,700,000
Deferred revenue — current					100,000
Deferred revenue — long term					1,600,000
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue' collaborations and services					$ 147,000	$ 147,000

[1] The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.